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Background:Methylation of histone H3 lysine 9 (H3K9) is commonly correlated with gene repression.
Results: p50 recruits EHMT1 to repress gene expression.
Conclusion: EHMT1 is a negative regulator of NF-B and type I interferon induction pathways.
Significance: p50-dependent changes in the chromatin structure importantly contribute to the repression of the expression
genes in resting cells.
Transcriptional homeostasis relies on the balance between
positive and negative regulation of gene transcription.Methyla-
tion of histone H3 lysine 9 (H3K9) is commonly correlated with
gene repression. Here, we report that a euchromatic H3K9
methyltransferase, EHMT1, functions as a negative regulator in
both the NF-B- and type I interferon-mediated gene induction
pathways. EHMT1 catalyzes H3K9methylation at promoters of
NF-B target genes.Moreover, EHMT1 interacts with p50, and,
surprisingly, p50 appears to repress the expression of type I
interferon genes and genes activated by type I interferons by
recruiting EHMT1 to catalyze H3K9 methylation at their pro-
moter regions. Silencing the expression of EHMT1 by RNA
interference enhances expression of a subset NF-B-regulated
genes, augments interferon production, and augments antiviral
immunity.
Covalent modifications of chromatin have emerged as key
determinants of the transcriptional competence of the genome.
Indeed, a strong correlation exists between the expression sta-
tus of a gene and specific histone modification (1). Although
histone methylation was discovered 4 decades ago (2), its phys-
iological role was unclear until recently. Site-specific methyla-
tions of specific histone residues correlate with either activa-
tion or repression of transcription. For example, H3K42
methylation is a mark of active genes, whereas H3K9 methyla-
tion has been correlated with gene repression (3–5).
There are seven known H3K9 histone methyltransferases
(H3K9-HMTs) in the human genome: SUV39H1, SUV39H2,
ESET, RIZ, EHMT1 (GLP), EHMT2 (G9a), and SETDB2. The
most studiedH3K9-HMTs are SUV39H1andSUV39H2,which
promote the formation of pericentric heterochromatin (6, 7).
Methylation of H3K9 by SUV39H1 creates a docking site for
subsequent binding of the heterochromatin protein HP1, pro-
viding compelling evidence linking H3K9 methylation to het-
erochromatin formation and transcriptional repression (8–10).
In contrast, we know that EHMT1 and EHMT2 are the major
euchromatic H3K9-HMTs because cells lacking either EHMT1
or EHMT2 showdecreasedH3K9me2 in euchromatin, whereas
the level of H3K9me2 remains unchanged in heterochromatin
(11, 12). EHMT1 is ubiquitously expressed. Knocking out the
EHMT1 gene in mice leads to embryonic lethality (12). The
global levels of H3K9me1 and H3K9me2, but not H3K9me3,
are lower in EHMT1-deficient ES cells than in wild-type ES
cells (12).However, it has been shown that EHMT1 is capable of
catalyzing formation ofH3K9me1,H3K9me2, andH3K9me3 in
an in vitromethyltransferase assay (13).
NF-B is a transcription factor that plays a pivotal role in
regulating multiple biological functions including inflamma-
tion, immunity, cell proliferation, and apoptosis. In resting
cells, NF- is sequestered in the cytoplasmby interactionwith
IB. Upon activation, IB is rapidly degraded by the ubiqui-
tin-proteasome pathway. Free NF-B is then translocated into
the nucleus where it turns on expression of a large array of
target genes (14, 15). Although inducible nuclear translocation
is critical for NF-B activation, many post-translational modi-
fications have been shown to regulate the nuclear function of
NF-B, including phosphorylation, ubiquitination, nitrosyla-
tion, acetylation, and methylation (16, 17).
We previously demonstrated that NF-B is positively regu-
lated by methylation of the p65 subunit (17). In this report, we
show that NF-B action as well as that of type I interferon are
negatively regulated by EHMT1. We show that the expression
of 44% of TNF-induced genes is enhanced in cells lacking
EHMT1. Using IL8 as a model, we further show that EHMT1 is
required for establishing H3K9 methylation at the IL8 pro-
moter. Furthermore, EHMT1 interacts with the p50 subunit of
NF-B. Surprisingly, p50 recruits EHMT1 to the promoters of
genes that respond to type I interferon and represses the
expression of these genes. Silencing the expression of either p50
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or EHMT1 augments interferon production and strengthens
the interferon-mediated inhibition of virus replication.
EXPERIMENTAL PROCEDURES
Cell Culture—HeLa, Human embryonic kidney (HEK) 293,
HEK293-PB1, A549-PB1, wild-type, and p50-deficient mouse
embryonic fibroblast (MEF) cells were cultured in DMEM sup-
plemented with 10% fetal calf serum (FCS), penicillin G (100
g/ml), and streptomycin (100 g/ml). Bone marrow-derived
macrophages (BMMs) were cultured as described earlier (18).
Antibodies—Antibodies against p65 (F6, C20), IB (C21),
p50 (H119, C19), JNK (C17), p38 (H147), HDAC1 (H-51), and
pol II (N20) were purchased from Santa Cruz Biotechnology.
Antibodies against FLAG (M2, Sigma), HA (Covance), p-JNK
(Cell Signaling), p-p38 (Cell Signaling), histone H3 (Abcam,
ab1791), H3K9me1 (Abcam, ab8896), H3K9me2 (Abcam,
ab1220), H3K9me3 (Abcam, ab8898), and EHMT1 (R&D Sys-
tems, Bethyl Laboratories) were purchased from the respective
commercial sources.
Flow Cytometry—A549-PB1 and 293T-PB1 cells were
infected with influenza virus for 12 h. Cells were washed and
fixed with paraformaldehyde (1% final). Fixed cells were
assayed using a BD FACScan flow cytometer (BD Biosciences)
and further analyzed with FlowJo software.
RT-PCR—Cells treated with TNF for 2 h were lysed with
TRIzol LS reagent (Invitrogen) to isolate total RNAs. cDNAs
were synthesized with the SuperScript III Reverse Transcrip-
tase kit (Invitrogen). Quantitative PCR was performed with the
2 SYBRGreenPCRMasterMix (AppliedBiosystems) and run
on theApplied BiosystemsABI 7300Real-timePCRSystem.All
data were normalized to L32. The sequences of the primers are
listed in supplemental Table S2.
RNA Interference—All siRNAs were purchased from Santa
Cruz Biotechnology: control (sc-37007), EHMT1a (sc-62261),
EHMT1b (Invitrogen HSS129760), ESET (sc-45659), RIZ (sc-
106513), SUV39H1 (sc-38463), SUV39H2 (sc-97240), SETDB2
(sc-62429), and p50 (sc-29407). The siRNA were transfected
into HEK293 or HeLa cells by calcium phosphate precipitation
at a final concentration of 10 nM. This procedure was repeated
the 2nd day to increase the efficiency of gene silencing. On the
3rd day, cells were serum-starved for 18 h before treating cells
with or without TNF.
ChIP Assay—ChIP assay was carried out using the Fast-ChIP
protocol with a slight modification (19). Briefly, cells were
cross-linked with 1% formaldehyde at room temperature for 10
min. Excess formaldehyde was neutralized by adding 1 ml of
1.25 M glycine at room temperature for 5 min. Cells were
washed three times with PBS and lysed in the hypotonic buffer.
The nuclei were isolated by centrifugation at 500 g 4 °C for 5
min and resuspended in 0.5 ml of SDS lysis buffer (50 mM Tris,
pH 8.0, 10 mM EDTA, and 1% SDS). DNAs were sheared by
sonication with a Branson 450 sonicator (output 2, 90% duty
cycle, 10 10-s pulse). Ten micrograms of sheared DNAs was
diluted with a 9 volume of dilution buffer (16.7 mM Tris, pH
8.0, 167 mM NaCl, 1.2 mM EDTA, 1% Triton X-100, 100 g/ml
salmon sperm DNA, and 2% BSA). Antibodies and Dynabeads
protein A (Invitrogen) were added and incubated at 4 °C for
12 h. The beads were then washed two times with a low salt
washing buffer (50 mM Tris, pH 7.5, 200 mM NaCl, 1% Triton
X-100, 2 mM EDTA, 0.5% Nonidet P-40) followed by two times
with a high salt washing buffer (50 mMHEPES, pH 7.9, 500 mM
NaCl, 1% Triton X-100, 0.1% SDS, 0.1% 2,5-dimethoxy-4-
chloramphetamine) and one time with TE buffer. The beads
were then resuspended with 100 l of 10% Chelex 100 beads,
and cross-linking was reversed by boiling the beads for 10 min.
The beads were then treated with 1 l of proteinase K and
incubated at 56 °C for 30min. The proteinase Kwas inactivated
by boiling for 10 min. Supernatants containing DNA were col-
lected, and the beads were washed with 120l of dH2O. Super-
natants were collected and analyzed by quantitative PCR. The
sequences of the primers are listed in supplemental Table S2.
Immunoprecipitation—For immunoprecipitation of EHMT1,
HEK293 cells were transfected with FLAG-tagged p65 or p50
along with HA-EHMT1. Twenty-four hours later, the cells were
lysed in radioimmune precipitation assay buffer (20 mM Tris, pH
7.5, 150mMNaCl, 1%Nonidet P-40, 0.5% 2,5-dimethoxy-4-chlor-
amphetamine, 0.1% SDS, 0.5 mM DTT, 0.5 mM PMSF, and 1
protease inhibitormixture (RocheApplied Science)). Twohun-
dred micrograms of lysates was incubated with 8 l of
FLAG-m2 beads (Sigma) or HA beads (F7, Santa Cruz Biotech-
nology) at 4 °C for 1 h. The beads were washed three times with
radioimmune precipitation assay buffer. Bound proteins were
examined by immunoblotting with FLAG or HA antibodies.
For immunoprecipitation of endogenous p65, p50, or
EHMT1, HEK293 cells were treated with TNF (10 ng/ml) and
harvested at different time points. The cytoplasmic extracts
were prepared using a hypotonic lysis buffer containing 0.2%
Nonidet P-40 (10 mM Tris, pH 7.5, 1.5 mM MgCl2, 10 mM KCl,
0.5 mM DTT, 0.5 mM PMSF, and 1 protease inhibitor mix-
ture). Thenuclear extractswere prepare by resuspending nuclei
inmicrococcus nuclease digestion buffer (50mMTris, pH 7.4, 1
mM CaCl2, 25 mM KCl, 4 mM MgCl2, 12.5% glycerol, 0.5 mM
DTT, 0.5 mM PMSF, and 1 protease inhibitor mixture). The
nuclear extracts were digested with MNase (90 units) at 37 °C
for 5min. The reaction was stop by adding 1 volume of 2 stop
solution (50 mM Tris, pH 7.4, 200 mM NaCl, 2 mM EDTA, 1%
Triton X-100). The nuclear extracts were precleared by incu-
bating with normal mouse or rabbit IgG and protein A/G-aga-
rose beads at 4 °C for 2 h. Endogenous p65, p50, or EHMT1was
immonoprecipitatedwith 20l of agarose-conjugated anti-p65
(F6), anti-p50 (H119), or EHMT1 (R&D) antibodies. Aftermix-
ing end-to-end at 4 °C for 2 h, the beads were washed three
times with PBS. Associated proteins were analyzed by immu-
noblotting with different antibodies as indicated.
Microarray—Formicroarray hybridization, 2g of RNAwas
labeled, fragmented, and hybridized to an Affymetrix
GeneChip Human Genome U133 Plus 2.0 Array. Data were
then analyzed with the Rosetta Resolver gene expression data
analysis system (Rosetta Inpharmatics). Expression differences
2-fold with a p value0.01 were considered significant. The
Gene Expression Omnibus accession number is GSE39744.
Statistical Analysis—Data were analyzed by Microsoft Excel
and are presented as themean S.D. Data are representative of
three or more independent experiments. Student’s t test was
used to determine significant differences between groups.
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RESULTS
EHMT1 Is an H3K9-HMT That Negatively Regulates the
NF-B Pathway—To test whether H3K9methylation regulates
NF-B-dependent gene expression, we silenced the expression
of every known H3K9-HMT in cells using RNA interference
(RNAi). Silencing the expression of EHMT1 but not other
H3K9-HMTs greatly enhanced TNF-induced expression of
several NF-B-dependent genes including A20, ICAM1, IL8,
FIGURE 1. EHMT1negatively regulates theNF-Bpathway.A, HeLa cells transfectedwith control or H3K9-HMTs-specific siRNAswere stimulatedwith TNF
for 2 h. The expression of A20, IB, IL8, ICAM1, and IP-10was measured by RT-PCR (*, p 0.05; **, p 0.01; ns, not significant). B, HeLa cells transfected with
control or EHMT1 siRNAs were treated with or without TNF for the indicated time periods. The expression of A20, IL8, and IP10was measured by RT-PCR. C,
BMMs were treated with or without BIX01294 for 24 h then treated with or without TNF for the indicated time periods. The expression of A20 and CCL5was
measured by RT-PCR.D, pie chart represents comparison of 124 TNF-induced genes between TNF-stimulated HeLa cells transfectedwith control or EHMT1
siRNAs. A–C, error bars represent the variation range of duplicate experiments.
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IP10, and IB (Fig. 1A) (20). The efficiency of the RNAi was
measured by RT-PCR, and 77–95% of knockdown efficiency
was achieved (supplemental Fig. S1A). Although knocking
down the expression of EHMT1 enhanced the expression of
this suite of genes, it did not affect their expression kinetics (Fig.
1B). For example, mRNA for the immediate early gene, A20,
was rapidly induced (peaked at 30 min) and then degraded,
whereas that of the late gene, IP10, was not detected until 2 h of
TNF stimulation and was further increased to 6 h, regardless of
the presence or absence of EHMT1. Similar results were
obtained when we treatedmouse BMMswith BIX01294, a spe-
cific inhibitor of EHMT1 and EHMT2, a closely related H3K9-
HMT (13, 21). The inhibition of EHMT1 in BMM led to
enhanced expression of A20 and CCL5 in response to TNF
stimulation (Fig. 1C). These results indicate that EHMT1 is the
major H3K9-HMT that negatively regulates the NF-B
pathway.
To minimize the possibility that the effect we observed with
EHMT1 RNAi was caused by an off-target effect, we tested two
different siRNAs specific for EHMT1 (a and b). We found that
TNF-induced IL8 expression was enhanced in cells trans-
fected with either EHTM1a or EHMT1b siRNAs, and 70–75%
knockdown efficiency was achieved with each (supplemental
Fig. S1B).
We next determined whether EHMT1 regulated NF-B
activity when it was induced by IL-1. As with TNF stimula-
tion, silencing the expression of EHMT1 greatly enhanced the
expression of A20, IP10, and IL8 induced by IL-1 stimulation
(supplemental Fig. S1C), suggesting that EHMT1 negatively
regulates NF-B activity induced by various forms of stimula-
tion.We further showed that depletion of EHMT1 blocked nei-
ther degradation of IB nor nuclear translocation of p65 (sup-
plemental Fig. S2A). In addition, TNF-induced activation of
JNK and p38 was also normal in EHMT1 siRNA-treated cells
(supplemental Fig. S2B) suggesting that the hyperresponsive-
ness of EHMT1-deficient cells is not due to increased receptor-
proximal signaling.
To examine the range of genes whose transcription is
affected by EHMT1, we evaluated the effects of EHMT1 loss of
function on TNF-induced gene expression by global gene
expression profiling. In response to TNF stimulation, 124
genes were up-regulated (2-fold) in control siRNA-treated
HeLa cells. Treatment with EHMT1-specific siRNA further
enhanced the levels of 55 genes (44%) (1.5-fold) whereas 53
genes (43%) were not affected to 1.5-fold, and the levels of 16
genes (13%) were reduced (Fig. 1C and supplemental Table S1).
It is evident that EHMT1 blockade augments transcription of
many genes in response to TNF induction.
EHMT1 Catalyzes H3K9 Methylation at the Promoters of
NF-B-regulated Genes—EHMT1 is a H3K9-HMT. In
EHMT1-deficient ES cells, the global H3K9me2 but not
H3K9me3 is reduced (12). Consistent with this observation,
silencing the expression of EHMT1 by RNAi led to a global
reduction ofH3K9me2but not ofH3K9me3 (Fig. 2A). Todeter-
mine whether EHMT1 catalyzes the H3K9 methylation at the
IL8 promoter, we first examinedwhen EHMT1 is present at the
IL8 promoter by a ChIP assay. Before induction, EHMT1 was
enriched at promoters of IL8 and -globin but not at the pro-
moter of GAPDH (Fig. 2B). EHMT1 was also evident in the
coding region of the IL8 gene. Knocking down the expression of
EHMT1byRNAi resulted in a 50% reduction of theChIP signal.
These results provide evidence that at the IL8 gene, EHMT1 is
present at the inactive locus before induction and reduced but
not eliminated by TNF induction.
We then analyzed the levels of H3K9me2 and H3K9me3 in
the control or EHMT1 siRNA-transfected cells treated with or
without TNF. In EHMT1-deficient cells, the basal levels of
H3K9me2 and H3K9me3 were reduced by 40% at the IL8 pro-
moter and exon, but not at the -globin promoter (Fig. 2C).
This reduction was not caused by nucleosome loss because the
data were normalized to the total level of histone H3. Further-
more, TNF inducedmore pol II recruitment to the IL8 gene in
EHMT1-deficient cells than in control siRNA-treated cells.
This is consistent with the observation that more IL8 was pro-
duced in EHMT1-deficient cells in response to TNF stimula-
tion (Fig. 1A). These results suggest that EHMT1 is the major
H3K9-HMT that catalyzes H3K9me2 and H3K9me3 at the IL8
gene. Although EHMT1 is present in the -globin promoter, it
is dispensable for methylating H3K9 at the -globin promoter.
EHMT1 Interacts with p50—We next tested whether
EHMT1 interacts with NF-B. We performed co-immunopre-
cipitation with lysates from HEK293 cells transfected with
EHMT1 and increasing amounts of FLAG-p65 or FLAG-p50.
Significantlymore EHMT1was present in FLAG-p50 immuno-
precipitates than in FLAG-p65 immunoprecipitates (Fig. 3A,
lanes 13–15 versus 16–18). In a reciprocal experiment, only
p50, but not p65, was detected in EHMT1 immunoprecipitates
(Fig. 3A, lanes 10–12 versus 7–9). These results indicate that
EHMT1 interacts strongly with p50 but weakly with p65.
p50 contains two functional domains, RHD-N and RHD-C.
To determine which domain of p50 is required for interacting
with EHMT1, we generated p50 fragments containing either
the RHD-N or RHD-C and performed co-immunoprecipita-
tion assay as described above. We found that only the RHD-N
of p50 interacted with EHMT1 (Fig. 3B, left panel). Because
RHD-N of p50 contains the DNA binding domain, we further
tested whether DNA binding is required for interacting with
EHMT1. We generated a DNA binding-deficient mutant
(p50Y60DG64E (22)) and showed that DNAbinding of p50was
dispensable for the binding to EHMT1 (Fig. 3B, right panel).
In contrast, EHMT1 contains an ankyrin repeat domain, a
Pre-SET, and a SET domain. To map the p50-interacting
domain, serial deletion mutants of EHMT1 were generated. A
fragment containing the ankyrin repeats (701–1108 amino
acids) was able to interact with p50 in the co-immunoprecipi-
tation assay (Fig. 3C), indicating that the ankyrin repeats are
responsible for the interactionwith p50. These findings provide
further evidence that EHMT1 interacts with p50.
To test whether endogenous p50 and EHMT1 form com-
plexes in cells, we carried out co-immunoprecipitation with
nuclear extracts prepared from cells treated with TNF for the
indicated time periods. Endogenous EHMT1 was detected in
p50 immunoprecipitates, regardless of TNF treatment, but
not in IgG or p65 immunoprecipitates (Fig. 3D). Interestingly,
p50 was detected in TNF-treated p65 immunoprecipitates;
however, no EHMT1 was detected, suggesting that EHMT1
Mechanism of EHMT1-mediated Gene Repression
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interacts with p50 homodimer constitutively but not with p65-
p50 heterodimer.
p50 Recruits EHMT1 to the Promoters of Type I Interferon-
responding Genes—The p50 homodimer, which lacks a trans-
activation domain, has been implicated in transcriptional
repression (23–25). Our data show that EHMT1negatively reg-
ulates NF-B target genes and interacts with p50. This suggests
that the p50 homodimer may function as a transcriptional
repressor by recruiting EHMT1 to the promoter of target genes
to promote H3K9 methylation. To test this hypothesis, we first
looked for genes that were up-regulated in both p50 and
EHMT1 knockdown cells. Surprisingly, we found that expres-
sion ofmany type I interferon-induced geneswere up-regulated
in EHMT1 knockdown cells (Fig. 4A). Some of these genes,
including IFN itself, CCL5, and IFIT2 were also up-regulated
in p50 knockdown cells (Fig. 4B). We further showed that the
rise in steady mRNA levels of ISGs is not due to an increase in
mRNA stability. We treated HeLa cells with BIX01294 for 24 h
followed by addition of actinomycin D. We then measured the
stability of mRNAs by RT-PCR and found that the mRNA sta-
bilities of IFIT2, IFIT3, andCCL5mRNAswere similar whether
cells were BIX01294-treated and not (supplemental Fig. S3A).
Importantly, TNF stimulation does not induce production of
IFN under normal conditions. In the absence of p50 or
EHMT1, TNF stimulation led to a 3-fold (p50-deficient) and
20-fold (EHMT1-deficient) increase of IFNmRNA.
FIGURE2.EHMT1promotesH3K9methylationatNF-Btargetgenes.A, 10or30gofnuclear extractsprepared fromHeLacells transfectedwithorwithout
EHMT1-specific siRNA was immunoblotted with the indicated antibodies, the data were quantified using ImageJ, and the relative protein levels are shown
(normalized with H3 protein level). B and C, HeLa cells transfected with control or EHMT1-specific siRNAs were stimulated with TNF for 60 min and were
analyzed by ChIP (EHMT1, pol II, H3K9me2/H3, and H3K9me3/H3; mean S.D. (error bars); *, p 0.05). Data are representative of three or more independent
experiments.
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To examine this phenomenon, we determined whether p50
was present at the promoters of IFN andCCL5 by ChIP. Using
wild-type and p50-deficient MEFs, we were able to detect a
3-fold increase compared with the knockout of the p50-medi-
ated signal at the promoter of IFN and CCL5 but not at the
promoter of -globin, which only showed a background ChIP
signal (Fig. 4C, top panel). In contrast, there was no enrichment
of p65 at these promoters (supplemental Fig. S3B). Moreover,
in the absence of p50, less EHMT1was bound to the promoters
of CCL5 (40% decrease) and IFN (50% decrease, Fig. 4C, sec-
ond panel). The level of EHMT1 at the promoter of -globin
was comparable between wild-type and p50-deficient MEFs.
Consistent with the decreased level of EHMT1, the levels of
H3K9me2 at the promoters of CCL5 and IFN were also
decreased in the p50-deficient MEFs (Fig. 4C, and data not
shown), whereas the levels of histone H3 remained unchanged
(Fig. 4C, bottom panel). Similar observations were made when
the expression of p50 was knocked down by RNAi in HeLa cells
(supplemental Fig. S3C). The levels of EHTM1 and H3K9me2
were decreased at the promoters of IFN and CCL5 in p50-
specific siRNA-treated HeLa cells. From these data, it appears
that p50 represses the expression of IFN and CCL5 in
response to TNF by recruiting EHMT1, which in turnmethy-
lates H3K9.
FIGURE 3. EHMT1 interacts with p50. A, HEK293 cells were transfectedwith EHMT1 alongwith increasing amounts of FLAG-p65 or FLAG-p50. EHMT1 (middle
panels) andFLAG (right panels) immunoprecipitates (IP) aswell as inputs (left panels)were immunoblotted (IB)with EHMT1andFLAGantibodies.B, HEK293 cells
were transfected with EHMT1 along with various fragments of p50 as indicated (left panel) or a DNA binding-defective mutant p50 (right panel). FLAG or IgG
immunoprecipitates and inputswere immunoblottedwith EHMT1 andp50 antibodies.Asterisks indicate different fragments of p50.HC, heavy chains; LC, light
chains.C, various deletionmutants of EHMT1alongwith FLAG-p50were co-transfected intoHEK293 cells. Inputs and FLAG immunoprecipitateswere analyzed
with HA and FLAG antibodies. Asterisks indicate different fragments of p50. D, endogenous p50 and p65 were immunoprecipitated from nuclear extracts
prepared fromHeLa cells treatedwith or without TNF for the indicated time periods. Immunoprecipitates were probedwith various antibodies as indicated.
IgG immunoprecipitates were used as a negative control.
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FIGURE 4. P50 recruits EHMT1 to the promoters of type I interferon-responding genes. A, heat map represents gene expression patterns of type I
interferon-responding genes amongHeLa cells transfectedwith control siRNA treatedwith TNF, or with EHMT1-specific siRNA treatedwith or without TNF
(*, p 0.05; **, p 0.01). B, HeLa cells transfected with control, EHMT1-, or p50-specific siRNAs were treated with or without TNF for 2 h. Expression of IFN,
CCL5, and IFIT2wasdeterminedbyRT-PCR (error bars represent the variation rangeof duplicate experiments).C, wild-type andp50/MEF cellswere analyzed
by ChIP (p50, EHMT1 and H3K9me2/H3; mean S.D., data are representative of three or more independent experiments; *, p 0.05).
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The ability of p50 to act as a transcriptional repressor
through the recruitment of HDAC1 has been reported to be a
mode of negative control of expression of some NF-B target
genes in resting cells (26). To test whether there is cross-talk
between HDAC1-mediated and EHMT1-mediated gene
repression, we inhibited the activity of HDAC1 and EHMT1
with TSA and RNAi, respectively. Pretreating the cells with
TSA led to higher expression ofA20 and IL8 but notTNF, IL6,
and IFN in response to TNF stimulation (supplemental Fig.
S3D). Interestingly, silencing the expression of EHMT1 with
RNAi further enhanced the expression of IL8 and A20 in the
presence of TSA. Furthermore, the recruitment of HDAC1 to
the promoters of A20, IL8, TNF, CCL5, -globin, and IFN
remained unchanged regardless of the presence or absence of
EHMT1 (supplemental Fig. S3E). These results indicate that
HDAC1-mediated and EHMT1-mediated gene repression are
independent of one another.
EHMT1 and p50 Are Negative Regulators of the Type I Inter-
feron Pathway—Viral infection of host cells triggers innate and
adaptive immune responses that are essential for the survival of
the host. IFN is particularly potent as an antiviral agent.
Because EHMT1 negatively regulates the expression of IFN,
we examined the possibility that EHMT1 could affect immune
defense against influenza virus. A nonreplicative WSN strain
influenza virus carrying mCherry in the place of the PB1 gene
was used to infect HEK293 cells stably expressing PB1 protein
(HEK293-PB1) (27). In HEK293-PB1 cells treated with a con-
trol siRNA, influenza virus infection induced the expression of
IFN, CCL5, and IFIT2 as measured by RT-PCR (Fig. 5A). The
expression of these genes was greatly enhanced in cells treated
with siRNAs against p50 or EHMT1. A similar result was
obtained when using p50-deficient MEF cells. Infecting the
wild-typeMEF cells with Sendai virus led to induction of IFN,
CCL5, and ISG20 (Fig. 5B). The expression of these genes was
further enhanced in p50-deficient MEF cells. These data con-
firm a negative role of EHMT1 and p50 in the type I interferon
pathway.
Knocking down the expression of p50 or EHMT1 in
HEK293-PB1 decreased the viral titer by 93 and 64%, respec-
tively, compared with control siRNA-treated cells (Fig. 5C). To
confirm the negative role of EHMT1 on influenza viral replica-
tion, we examined the anti-viral effect of BIX01294, a specific
inhibitor of EHMT1 and EHMT2, a closely relatedH3K9-HMT
(13, 21). We pretreated the A549-PB1 cells with BIX01294 for
48 h and infected the cells with influenza virus at a multiplicity
of infection (m.o.i.) of 1. After 24 h, infected cells were quanti-
fied by sorting the virus-infected, mCherry-positive cells using
FACS. Pretreating cells with BIX01294 strongly inhibited the
viral infection (Fig. 5D). A similar result was observed when
using vesicular stomatitis virus. Infection ofHeLa cells by vesic-
ular stomatitis virus led to nearly complete killing of the cells
within 24 h at am.o.i. of 0.05 (supplemental Fig. S4A). Pretreat-
ing cells with BIX01294 prevented cell killing by vesicular sto-
matitis virus even at a m.o.i. of 1. In addition, we found that the
level of H3K9me2 but notH3K9me3was reduced in BIX01294-
pretreated cells, confirming the inhibition of EHMT1 by
BIX01294 (supplemental Fig. S4B). Furthermore, we found that
the basal level of type I interferon response genes, including
CCL5, IFN, IFIT2, IFIT3, and ISG20, was up-regulated in
BIX01294-treated cells (Fig. 5E), implying that inhibition of
EHMT1 activity leads to up-regulation of antiviral genes which
in turn protects cells from viral infection. These findings fur-
ther support the negative role of p50 and EHMT1 in the type I
interferon pathway.
DISCUSSION
We have found that the histone methylase EHMT1 is able to
negatively regulate a large fraction, but not all, of NF-B-regu-
lated genes. Silencing of EHMT1 causes superactivation of the
genes its regulates. It does this through interactionwith the p50
subunit of NF-B. Surprisingly, it is carried to the promoters of
certain IFN-regulated genes by p50, where it exerts its negative
effect on transcription. IFN itself is one of the regulated genes
so that silencing of EHMT1 or p50 augments induces produc-
tion of excess interferon and remarkably strengthens the inhi-
bition of viral infection.
Our findings support a model in which p50-dependent
changes in the chromatin structure of the type I interferon
response genes importantly contribute to the repression of the
expression of these genes in resting cells. This is consistent with
the notion that p50 homodimers are involved in preinduction
repression of IFN gene transcription as well as subset of inter-
feron-responding genes (28–31). The function of p50 as a tran-
scriptional repressor involving the recruitment of HDAC1 has
been reported to repress the expression of some NF-B target
genes in resting cells (26). Here we demonstrated an alternative
mechanism involving the recruitment of EHMT1 by p50 to the
promoters of IFN andCCL5. EHMT1 in turn promotes H3K9
methylation and results in the formation of chromatin struc-
ture that represses transcription (Fig. 6A). How is p50 recruited
to the promoters of type I interferon response genes? STAT1 is
one of the key transcription factors in the interferon pathway
that regulates expression of type I interferon response genes
through binding to the IREs (32). It is possible that STAT1may
play a role in recruiting p50 to the promoters of the type I
interferon response genes. However, we failed to detect any
interaction between p50 and STAT1 (data not shown), and a
recent study has shown that p50 binds toG-rich IREs (30). Thus
we think that p50 represses type I interferon response genes by
directly binding to G-rich IREs. P50 has been shown to bind to
some of the NF-B target genes in unstimulated cells (33). P50
may also recruit EHMT1 to repress the expression of a subset of
TNF-induced NF-B target genes (Fig. 6A). In addition,
EHMT1 can also inhibit the expression of NF-B target genes
independent of p50. For example, we were unable to detect any
binding of p50 at the promoters of IL8 and IP10 in resting cells
(data not shown). The involvement of p50 in the repression of
IL8 and IP10 is very unlikely. Thus it seems that EHMT1 is
recruited in some other way to the promoters certain NF-B
target genes (Fig. 6B). It could involve an undetermined factor
X. One strong candidate for X is the p65 subunit of NF-B as it
has been recently shown that methylated p65 (p65K310me1)
was able to repress the expression of subset NF-B target genes
in resting cells by recruiting EHMT1 (34).
Negative regulation of transcription is an important strategy
in establishing and maintaining cell- and signal-specific gene
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expression patterns. Our study indicates that EHTM1 is critical
not only for silencing the expression of NF-B-regulated genes
and type I interferon-responding genes, but also for establish-
ing the signal specificity of gene expression. It has been ele-
gantly shown that different immunostimuli induce different
gene expression patterns (35). For example, PAM induces an
FIGURE 5. EHMT1- and p50-deficient cells are resistant to viral infection. A, HEK293-PB1 cells transfectedwith control siRNA or EHMT1-specific siRNAwere
infected with influenza virus at a m.o.i. of 0.5 for 18 h. The expression of IFN, CCL5, and IFIT2was determined by RT-PCR, *, p 0.05; **, p 0.01. B, wild-type
or p50-deficient MEF cells were infected with Sendai virus for 18 h. The expression of CCL5, IFN, and ISG20wasmeasured by RT-PCR, *, p 0.05; **, p 0.01.
C, the culture supernatants from Awere collected and were used to infect A549-PB1 cells. Twelve hours later, mCherry-positive cells were sorted by FACS (**,
p 0.01).D, A549-PB1 cells were treatedwith dimethyl sulfoxide (DMSO) or 5M BIX01294 for 48 h. The cells were then infectedwith influenza virus at am.o.i.
of 1.0 for 24h.mCherry-positive cellswere sortedbyFACS. Chart representsquantificationof three independentbiological samples (meanS.D.) (**,p0.01).
E, A549-PB1 cells were treated as in D. The basal levels of IFN, CCL5, IFIT2, IFIT3, and ISG20 were measured by RT-PCR. A, B, and E, error bars represent the
variation range of duplicate experiments (*, p 0.05; **, p 0.01).
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“inflammatory-like” program, whereas poly(I:C) induces an
“anti-viral” program, and LPS induces both the inflammatory-
like and the anti-viral programs (35). Under normal conditions,
the expression of IFN is induced specifically by a few NF-B
agonists, such as LPS and poly(I:C) but not TNF and IL1. In
the absence of EHMT1, the expression of IFN is induced by
treating the cells with TNF or IL1, suggesting that EHMT1 is
required for establishing the signal-specific induction of IFN
(Fig. 4B and data not shown). Another consequence of using
EHTM1 to maintain and establish signal-specific gene expres-
sion is that the capacity of gene induction is limited. For exam-
ple, in response to TNF stimulation, the expression of IL8
(3-fold) and IP10 (2-fold) is higher in cells without the negative
regulation of EHMT1 (Fig. 1A).
Our results show that EHMT1 is a negative regulator of type
I interferon pathway (Figs. 4 and 5) and thus might be a poten-
tial new target for developing new antivirus drugs. Indeed,
pharmacological inhibition of EHMT1with BIX01294 protects
cells from virus infection (Fig. 5D). However, EHMT1 has been
implicated in playing a role in control of cognition and adaptive
behavior in adult mice (36). Conditional EHMT1 and EHMT2
gene inactivation in postnatal mouse neurons led to defects in
learning, motivation, and environmental adaptation (36), sug-
gesting that long term inhibition of EHMT1might affect proper
brain functions. Furthermore, EHMT2 has been shown to be
involved in cocaine-induced plasticity, and treating mice with
BIX01294 increased the preference for cocaine (37). Thus, the
potential of using BIX01294 as an antiviral drug might be com-
promised by adverse side effects related to the biological roles
of EHMT1 in other systems such as the CNS. Developing an
inhibitor that inhibits the binding between EHMT1 and p50
rather than the enzymatic activity of EHMT1might be better a
strategy but would be very difficult. Further experimentation
using animal models will be needed to examine the clinical
application of EHMT1 inhibitors.
In preparation of our manuscript, Fang et al. identified
EHMT2 (G9a) as a negative regulator of the type I interferon
response (38). It has been shown that EHMT1 and EHMT2
form a homodimer and heterodimer in vivo, and deficiency of
either EHMT1 or EHMT2 in ES cells results in global reduction
of H3K9me2 (39). Therefore, it seems that the EHMT1/
EHMT2 heterodimer is the functional H3K9methyltransferase
in vivo. Our results indicate that EHMT2 in dispensable for the
NF-B pathway (Fig. 1A), whereas both EHMT1 and EHMT2
are required for repressing type I interferon pathway (Figs. 4
and 5 and Ref. 38).
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